Genomic signature to guide adjuvant chemotherapy treatment decisions for early breast cancer patients in France: a cost-effectiveness analysis.

Curtit, Elsa; Bellanger, Martine Marie; Nerich, Virginie; Hequet, Delphine; Frenel, Jean-Sebastien; Cristeau, Olivier; Rouzier, Roman

Curtit, Elsa; Bellanger, Martine Marie; Nerich, Virginie; Hequet, Delphine; Frenel, Jean-Sebastien; Cristeau, Olivier; Rouzier, Roman.

Affiliation

Curtit E; University of Franche-Comté, University Hospital of Besançon J. Minjoz, INSERM, EFS UMR 1098, Besançon, France.
Bellanger MM; UMR CNRS6051, Ecole des Hautes Etudes en Santé Publique - School of Public Health (EHESP), University of Rennes, Rennes, France.
Nerich V; Department of Pharmacy, University Hospital of Besançon, France; INSERM, EFS-BFC, UMR 1098, University of Franche-Comté, Besançon, France.
Hequet D; Institut Bourdonnais, Clinique Saint Jean de Dieu, Paris, France.
Frenel JS; Institut de Cancérologie de l'Ouest, Saint Herblain, France.
Cristeau O; Creativ-Ceutical, Paris, France.
Rouzier R; Centre François Baclesse, Caen, France.

Front Oncol ; 13: 1191943, 2023.

Article in En | MEDLINE | ID: mdl-37427133

Key words

adjuvant chemotherapy; cost-effectiveness analysis; decision impact; early breast cancer; genomic signatures

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Type of study: Health_economic_evaluation / Prognostic_studies / Qualitative_research / Risk_factors_studies Language: En Journal: Front Oncol Year: 2023 Type: Article Affiliation country: France

Fulltext

XML

PubMed Links

Search on Google